MCID: HDR003
MIFTS: 49

Hidradenitis

Categories: Endocrine diseases, Skin diseases

Aliases & Classifications for Hidradenitis

MalaCards integrated aliases for Hidradenitis:

Name: Hidradenitis 12 43 15 71
Hydradenitis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2282
ICD9CM 34 705.83
MeSH 43 D016575
NCIt 49 C112190
SNOMED-CT 67 69741000
UMLS 71 C0085160

Summaries for Hidradenitis

Disease Ontology : 12 A sweat gland disease that is characterized by inflammation of the apocrine sweat glands and has symptom erythema, edema, papules, plaques, pruritis, and pain.

MalaCards based summary : Hidradenitis, also known as hydradenitis, is related to crohn's colitis and pyoderma, and has symptoms including erythema An important gene associated with Hidradenitis is NCSTN (Nicastrin), and among its related pathways/superpathways are Innate Immune System and Developmental Biology. The drugs Adalimumab and Spironolactone have been mentioned in the context of this disorder. Affiliated tissues include skin, neutrophil and myeloid, and related phenotypes are cellular and growth/size/body region

Wikipedia : 74 Hidradenitis is any disease in which the histologic abnormality is primarily an inflammatory infiltrate... more...

Related Diseases for Hidradenitis

Diseases related to Hidradenitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 529)
# Related Disease Score Top Affiliating Genes
1 crohn's colitis 31.0 TNF NOD2 IFNG
2 pyoderma 30.7 TNF NOD2 DSG3 DSG1
3 crohn's disease 30.6 TNF TLR4 NOD2 IL17A IFNG
4 arthropathy 30.5 TNF LTA IFNG
5 keratitis, hereditary 30.5 TNF TLR4 IL17A
6 familial mediterranean fever 30.2 TNF TLR4 NOD2 IL17A
7 spondyloarthropathy 30.2 TNF LTA IL17A IFNG
8 bone inflammation disease 30.2 TNF TLR4 IL17A IFNG
9 spondyloarthropathy 1 30.1 TNF TLR4 NOD2 IL17A
10 ulcerative colitis 30.1 TNF TLR4 NOD2 IL17A IFNG
11 filariasis 30.0 TNF TLR4 IFNG
12 pachyonychia congenita 1 30.0 KRT14 KRT10 DSG1
13 chorioretinitis 30.0 TNF IL17A IFNG
14 osteomyelitis 30.0 TNF TLR4 NOD2 IFNG
15 reactive arthritis 30.0 TNF TLR4 IL17A IFNG
16 pulmonary sarcoidosis 29.9 TNF IL12RB1 IFNG
17 urethritis 29.8 TNF TLR4 CAMP
18 inflammatory bowel disease 1 29.8 TNF TLR4 NOD2
19 common cold 29.8 TNF TLR4 IL17A
20 spondylitis 29.8 TNF NOD2 LTA IL17A IFNG
21 spondylarthropathy 29.8 TNF TLR4 NOD2 LTA
22 colitis 29.8 TNF TLR4 NOD2 IL17A IFNG
23 myositis 29.7 TNF PSEN1 IL17A IFNG
24 chlamydia 29.7 TNF TLR4 IL17A IFNG
25 candidiasis 29.7 TNF TLR4 IL17A IFNG
26 endocarditis 29.7 TNF KRT10 IL17A IFNG
27 allergic hypersensitivity disease 29.7 TNF TLR4 IL17A IFNG
28 sweat gland disease 29.6 PIP NCSTN KRT14
29 alopecia areata 29.6 TNF IL17A IFNG
30 uveitis 29.6 TNF NOD2 LTA IL17A IFNG
31 keratoacanthoma 29.6 KRT14 KRT10 DSG1
32 bacterial meningitis 29.5 TNF TLR4 IL17A IFNG
33 meningitis 29.5 TNF TLR4 IL17A IFNG
34 bacterial infectious disease 29.5 TNF TLR4 NOD2 IL17A IFNG CAMP
35 periodontitis 29.5 TNF TLR4 IL17A IFNG
36 monocytic leukemia 29.5 TNF TLR4 IFNG
37 granulomatosis with polyangiitis 29.4 TNF TLR4 IL17A
38 psoriasis 29.4 TNF NOD2 LTA KRT14 KRT10 IL17A
39 sarcoidosis 1 29.4 TNF NOD2 LTA IL12RB1 IFNG
40 dermatitis 29.3 TNF TLR4 NOD2 IL17A IFNG DSG1
41 lymphadenitis 29.2 TNF TLR4 NOD2 IL12RB1 IFNG
42 inflammatory bowel disease 29.2 TNF TLR4 NOD2 LTA IL17A IL12RB1
43 arthritis 29.2 TNF TLR4 NOD2 LTA IL17A IFNG
44 bullous pemphigoid 29.2 KRT14 DSG3 DSG1
45 peritonitis 29.2 TNF TLR4 IFNG
46 psoriatic arthritis 29.0 TNF TLR4 NOD2 LTA IL17A IFNG
47 autoimmune disease 29.0 TNF LTA IL17A IFNG DSG3 DSG1
48 eye disease 29.0 TNF TLR4 KRT14 IL17A IFNG
49 cellulitis 28.9 TNF DSG3 DSG1 DSC2 DSC1 CAMP
50 skin disease 28.8 TNF TLR4 KRT14 KRT10 IL17A IFNG

Graphical network of the top 20 diseases related to Hidradenitis:



Diseases related to Hidradenitis

Symptoms & Phenotypes for Hidradenitis

Symptoms:

12
  • erythema

MGI Mouse Phenotypes related to Hidradenitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.22 CAMP DSC1 DSG3 IFNG KRT14 NCSTN
2 growth/size/body region MP:0005378 10.22 DSC1 DSG1 DSG3 IFNG IL12RB1 IL17A
3 hematopoietic system MP:0005397 10.18 CAMP DSG3 IFNG IL12RB1 IL17A KRT14
4 immune system MP:0005387 10.17 CAMP DSC1 DSG3 IFNG IL12RB1 IL17A
5 digestive/alimentary MP:0005381 10.09 DSG3 IFNG IL17A KRT14 NOD2 PIP
6 craniofacial MP:0005382 10.06 DSC1 DSG3 IFNG IL17A KRT14 NCSTN
7 integument MP:0010771 10 DSC1 DSG1 DSG3 IFNG IL12RB1 IL17A
8 respiratory system MP:0005388 9.76 DSG3 IFNG IL17A KRT14 LTA PSEN1
9 skeleton MP:0005390 9.61 DSG1 DSG3 IFNG IL17A LTA NOD2
10 vision/eye MP:0005391 9.4 CAMP DSC1 DSC2 DSG1 DSG3 IFNG

Drugs & Therapeutics for Hidradenitis

Drugs for Hidradenitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 82)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Adalimumab Approved Phase 4 331731-18-1 16219006
2
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
3 Anesthetics Phase 4
4 Anti-Inflammatory Agents Phase 4
5 Antirheumatic Agents Phase 4
6 Potassium Supplement Phase 4
7 Antibodies, Monoclonal Phase 3
8 Immunologic Factors Phase 3
9 Immunoglobulins Phase 3
10 Antibodies Phase 3
11 Antibiotics, Antitubercular Phase 3
12 Anti-Bacterial Agents Phase 3
13
Etanercept Approved, Investigational Phase 2 185243-69-0
14
Infliximab Approved Phase 2 170277-31-3
15
Ustekinumab Approved, Investigational Phase 2 815610-63-0
16
Apremilast Approved, Investigational Phase 2 608141-41-9 11561674
17
Hydroxychloroquine Approved Phase 1, Phase 2 118-42-3 3652
18 Brodalumab Approved, Investigational Phase 2 1174395-19-7
19
Polyestradiol phosphate Approved Phase 2 28014-46-2
20
Estradiol Approved, Investigational, Vet_approved Phase 2 50-28-2 5757
21
Drospirenone Approved Phase 2 67392-87-4 68873
22
Ethinyl Estradiol Approved Phase 2 57-63-6 5991
23
Glutamic acid Approved, Nutraceutical Phase 2 56-86-0 33032
24 Anti-Inflammatory Agents, Non-Steroidal Phase 2
25 Analgesics, Non-Narcotic Phase 2
26 Gastrointestinal Agents Phase 2
27 Immunosuppressive Agents Phase 2
28 Analgesics Phase 2
29 Interleukin 1 Receptor Antagonist Protein Phase 2
30 Angiogenesis Inhibitors Phase 2
31 lysine Phase 2
32 Complement System Proteins Phase 2
33 Complement C5a Phase 2
34 Anti-Infective Agents Phase 1, Phase 2
35 Antiparasitic Agents Phase 1, Phase 2
36 Antiprotozoal Agents Phase 1, Phase 2
37 Antimalarials Phase 1, Phase 2
38 Dermatologic Agents Phase 2
39 Pharmaceutical Solutions Phase 2
40 Epidiolex Phase 2
41 chlorophyllin Phase 2
42 Olive Phase 2
43 Hormone Antagonists Phase 2
44 Hormones Phase 2
45 Natriuretic Agents Phase 2
46 Mineralocorticoids Phase 2
47 Mineralocorticoid Receptor Antagonists Phase 2
48 diuretics Phase 2
49 Diuretics, Potassium Sparing Phase 2
50 Estrogens Phase 2

Interventional clinical trials:

(show top 50) (show all 93)
# Name Status NCT ID Phase Drugs
1 A Phase 4, Double-blind, Randomised, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Adalimumab Used in Conjunction With Surgery in Subjects With Moderate to Severe Hidradenitis Suppurativa Completed NCT02808975 Phase 4 Adalimumab;Placebo
2 Cost-effectiveness of Adalimumab With Adjuvant Surgery Versus Adalimumab Monotherapy in the Treatment of Hidradenitis Suppurativa' Recruiting NCT03221621 Phase 4 Adalimumab Injection
3 Spironolactone in the Treatment of Hidradenitis Suppurativa: A Prospective, Open-Label Proof-of-Concept and Dose-Ranging Study Not yet recruiting NCT04100083 Phase 4 Spironolactone 50 MG;Spironolactone 100mg;Spironolactone 200 mg
4 Hidradenitis Suppurativa Patients' Experience of Treatment With Adalimumab Not yet recruiting NCT04132388 Phase 4 Adalimumab
5 A Phase 3, Open-Label Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER (Open-Label Extension) Completed NCT01635764 Phase 3
6 A Phase 3 Multicenter, Open-label, Single Arm Study of the Safety and Efficacy of Adalimumab in Japanese Subjects With Moderate to Severe Hidradenitis Suppurativa Completed NCT02904902 Phase 3 adalimumab
7 A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER II Completed NCT01468233 Phase 3
8 A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER I Completed NCT01468207 Phase 3
9 A Single Center Clinical Trial to Evaluate the Effect of Sclerotherapy on Fistulas and Sinus Tracts in Adult Patients With Hidradenitis Suppurativa Recruiting NCT02805595 Phase 3 23.4% Hypertonic saline;Saline
10 A Randomized, Double-blind, Multicenter Study Assessing Short (16 Weeks) and Long-term Efficacy (up to 1 Year), Safety, and Tolerability of 2 Subcutaneous Secukinumab Dose Regimens in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (SUNRISE) Recruiting NCT03713632 Phase 3 Secukinumab
11 A Randomized, Double-blind, Multi-center Study Assessing Short (16 Weeks) and Long-term Efficacy (up to 1 Year), Safety, and Tolerability of 2 Subcutaneous Secukinumab Dose Regimens in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (SUNSHINE). Recruiting NCT03713619 Phase 3 secukinumab
12 A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to Demonstrate Long-term Efficacy, Safety and Tolerability in Subjects With Moderate to Severe Hidradenitis Suppurativa Not yet recruiting NCT04179175 Phase 3 secukinumab
13 To Determine The Efficacy Of A 1320nm Nd: YAG Nonablative Laser For Treatment of Hidradenitis Suppurativa Terminated NCT00367328 Phase 3
14 A Phase 2 Study of the Safety and Efficacy of Etanercept for the Therapy of Hydradenitis Suppurativa Completed NCT00329823 Phase 2 Etanercept sc 50mg per week for 12 weeks
15 A Phase 2, Open-Label, Single-Arm Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa Completed NCT03569371 Phase 2 INCB054707
16 A Phase 2 Multicenter, Investigator-Blind, Subject-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa Completed NCT03248531 Phase 2 Bimekizumab;Adalimumab
17 Phase 2 Study to Assess the Safety and Efficacy of Infliximab for the Treatment of Hidradenitis Suppurativa Completed NCT00795574 Phase 2 infliximab;Placebo Comparator
18 A Randomized, Double-blind, Placebo Controlled, Multiple Dose Study to Evaluate the Clinical Efficacy, Safety, Tolerability, Dose Relation, Pharmacokinetics and Pharmacodynamics of CJM112 in Moderate to Severe Chronic Hidradenitis Suppurativa Patients Completed NCT02421172 Phase 2 Placebo
19 Open Label,Phase Two Study to Assess the Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa Completed NCT00827996 Phase 2 adalimumab
20 A Prospective Proof of Concept Study to Evaluate the Potential Efficacy of Ustekinumab in Patients With Moderate to Severe Hidradenitis Suppurativa (Acne Ectopica) Completed NCT01704534 Phase 2 Ustekinumab
21 An Open Label Phase II Trial to Evaluate the Safety of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa Completed NCT03001622 Phase 2
22 An Open Label Non-randomized Study Assessing the Efficacy and Tolerability of Fixed-dose Regimen Daily Subcutaneous Anakinra for the Treatment of Moderate to Severe Hidradenitis Suppurativa Completed NCT01516749 Phase 2 anakinra
23 A Phase II Open Label Clinical Trial of Etanercept for the Treatment of Hidradenitis Suppurativa Completed NCT00107991 Phase 2 etanercept
24 Short-term Safety, Efficacy and Mode of Action of Apremilast in Moderate Suppurative Hidradenitis: A Randomised Double-blind Placebo Controlled Trial Completed NCT03049267 Phase 2 Apremilast;Placebo Oral Tablet
25 A Phase 2 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa Completed NCT00918255 Phase 2 Placebo
26 A Phase 2 Open-label Single Center Study to Evaluate the Efficacy of Apremilast for the Treatment of Moderate Hidradenitis Suppurativa Completed NCT02695212 Phase 2 Apremilast
27 A Double-blind, Randomized, Placebo-controlled Clinical Trial of the Safety and Efficacy of Anakinra in Patients With Hidradenitis Suppurativa Completed NCT01558375 Phase 2 Water for injection;Anakinra
28 A Double-blind, Randomised, Placebo-controlled Clinical Trial of the Efficacy of MABp1, a- First-in-class True Human Antibody Targeting Interleukin-1alpha, in Patients With Hidradenitis Suppurativa Not Eligible for antiTNF Therapy Completed NCT02643654 Phase 2 MABp1;Placebo
29 A Randomized, Subject and Investigator Blinded, Placebo-controlled and Multi-center Platform Study, to Assess Efficacy and Safety of Different Investigational Drugs in Patients With Moderate to Severe Hidradenitis Suppurativa Recruiting NCT03827798 Phase 2 CFZ533;Placebo to CFZ533;LYS006;Placebo to LYS006
30 A Phase 2, Dose-Escalation, Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa Recruiting NCT03607487 Phase 2 INCB054707;Placebo
31 A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients With Moderate to Severe Hidradenitis Suppurativa Recruiting NCT04019041 Phase 2 bermekimab;placebo
32 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Risankizumab in Adult Subjects With Moderate to Severe Hidradenitis Suppurativa Recruiting NCT03926169 Phase 2 Risankizumab;Placebo for risankizumab
33 A Phase II, Open Label Study of Bermekimab in Patients With Moderate to Severe Hidradenitis Suppurativa Recruiting NCT03512275 Phase 2 Bermekimab Monoclonal Antibody 400 mg
34 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa Recruiting NCT03852472 Phase 2 Avacopan
35 Clinical Efficacy of Inhibition of Organ Dysfunction Through Bermekimab in Systemic Sclerosis: A Proof- Of-Concept Double-Blind Randomized Clinical Trial (the Light Trial) Recruiting NCT04045743 Phase 2 MABp1 (Bermekimab) OR Placebo;MABp1 (Bermekimab)
36 A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Determine Efficacy and Safety of IFX-1 in Subjects With Moderate to Severe Hidradenitis Suppurativa Active, not recruiting NCT03487276 Phase 2 IFX-1;Placebo
37 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects With Moderate to Severe Hidradenitis Suppurativa Active, not recruiting NCT03628924 Phase 2 Guselkumab dose 1;Guselkumab dose 2;Guselkumab dose 3;Placebo
38 Pilot Study of Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa Active, not recruiting NCT03275870 Phase 1, Phase 2 Hydroxychloroquine
39 Guselkumab for Hidradenitis Suppurativa, a Mode of Action Study. The HiGUS-trial Not yet recruiting NCT04061395 Phase 2
40 A PHASE 2A, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 16-WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF PF-06650833, PF-06700841, AND PF-06826647 IN ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA Not yet recruiting NCT04092452 Phase 2 PF-06650833;PF-06700841;PF-06826647;Placebo
41 A Phase Ⅱ, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabis Oil for the Treatment of Subjects With Hidradenitis Suppurativa Not yet recruiting NCT03929835 Phase 2 Cannabis oil;Placebo
42 An Open-label Single Center Study to Evaluate the Efficacy of SILIQ™ (Brodalumab) for the Treatment of Moderate Hidradenitis Suppurativa Not yet recruiting NCT03910803 Phase 2 Brodalumab
43 A Phase IIa Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability and Preliminary Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa Terminated NCT01838499 Phase 2
44 A Single-Center, Randomized Double-Blind, Parallel-Group Study to Examine the Safety and Efficacy of YAZ Compared With Placebo In The Treatment Of Hidradenitis Suppurativa Terminated NCT00722800 Phase 2 drospirenone and ethinyl estradiol (YAZ);Placebo
45 An Open-Label Assessment of the Efficacy & Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa Completed NCT00134134 Phase 1 efalizumab
46 A Multicenter, Open-label, 2-regimen, Repeat-dose Study to Assess the Safety and Pharmacokinetics of Intravenous CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis Recruiting NCT03972280 Phase 1
47 A Phase I, Randomized, Open-label, Parallel-group Study to Determine the Pharmacokinetics, Safety, and Tolerability of MSB11022 (Proposed Adalimumab Biosimilar) Following a Single Subcutaneous Injection by an Auto-injector or by a Pre-filled Syringe in Healthy Subjects Recruiting NCT04018599 Phase 1 40 mg MSB11022;40 mg MSB11022
48 A Comparative Retrospective Study Between Patients With Hidradenitis vs Patients With Psoriasis: Psychological Impact Unknown status NCT02999698
49 Group Psychotherapy for Patients With Hidradenitis Suppurativa: Effects in Quality Unknown status NCT02904408
50 The Effect of Intense Pulsed Light Assisted Hair Removal Therapy on Mild and Moderate Cases of Hidrosadenitis Suppurativa Unknown status NCT03203122

Search NIH Clinical Center for Hidradenitis

Cochrane evidence based reviews: hidradenitis

Genetic Tests for Hidradenitis

Anatomical Context for Hidradenitis

MalaCards organs/tissues related to Hidradenitis:

40
Skin, Neutrophil, Myeloid, T Cells, Bone, Thyroid, Breast

Publications for Hidradenitis

Articles related to Hidradenitis:

(show top 50) (show all 2687)
# Title Authors PMID Year
1
Anti-tumor necrosis factor (TNF)-induced lupus in a patient with hidradenitis suppurativa. 61
31633193 2020
2
Work productivity and activity impairment in patients with hidradenitis suppurativa: a cross-sectional study. 61
31736064 2020
3
Identification of bacterial DNA in the peripheral blood of patients with active hidradenitis suppurativa. 61
31422449 2020
4
Biologics for chronic inflammatory skin diseases: an update for the clinician. 61
30827126 2020
5
Off-label studies on apremilast in dermatology: a review. 61
30935262 2020
6
Tofacitinib shows benefit in conjunction with other therapies in recalcitrant hidradenitis suppurativa patients. 61
31993474 2020
7
Clinical, microbiological, immunological and imaging characteristics of tunnels and fistulas in hidradenitis suppurativa and Crohn's disease. 61
31519056 2020
8
Type 2 diabetes mellitus in a cohort of Finnish patients with hidradenitis suppurativa. 61
31596976 2020
9
Hidradenitis Suppurativa in Sweden: A Registry-Based Cross-Sectional Study of 13,538 Patients. 61
32015234 2020
10
Successful treatment of recalcitrant gluteal hidradenitis suppurativa with brodalumab after anti-TNF failure. 61
32012238 2020
11
Standing up together to the shame and stigma associated with hidradenitis suppurativa. 61
31789426 2020
12
Dietary and metabolic factors in the pathogenesis of hidradenitis suppurativa: a systematic review. 61
31651051 2020
13
Thyroid disorders in patients with hidradenitis suppurativa: A systematic review and meta-analysis. 61
31310843 2020
14
Factors influencing the local cure rate of hidradenitis suppurativa following wide local excision. 61
31680472 2020
15
Hidradenitis Suppurativa and Bipolar Disorders: A Role for Lithium Therapy? 61
32036365 2020
16
Hidradenitis suppurativa and pemphigus: a cross-sectional study. 61
32034471 2020
17
Characterizing inpatient hospitalizations for hidradenitis suppurativa in the United States. 61
31541745 2020
18
Complementary and alternative medicine use in hidradenitis suppurativa. 61
31396946 2020
19
Concordance of severity scores for photographic assessment of hidradenitis suppurativa. 61
31494929 2020
20
A qualitative analysis of psychological distress in hidradenitis suppurativa. 61
31099891 2020
21
Evaluating patients' unmet needs in hidradenitis suppurativa: Results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project. 61
31279015 2020
22
Association between obesity and hidradenitis suppurativa among children and adolescents: A population-based analysis in the United States. 61
31442534 2020
23
Low-dose methotrexate as rescue therapy in patients with hidradenitis suppurativa and pyoderma gangrenosum developing human antichimeric antibodies to infliximab: A retrospective chart review. 61
31541746 2020
24
A novel NCSTN missense mutation in the signal peptide domain causes hidradenitis suppurativa, which has features characteristic of an autoinflammatory keratinization disease. 61
31421058 2020
25
AKT-dependent hyperproliferation of keratinocytes in familial hidradenitis suppurativa with a NCSTN mutation: a potential role of defective miR-100-5p. 61
31448409 2020
26
A case of Atopic dermatitis and Hidradenitis Suppurativa successfully treated with Dupilumab. 61
32034813 2020
27
Prevalence of inflammatory bowel disease (IBD) in hidradenitis suppurativa (HS): systematic review and adjusted meta-analysis. 61
31631340 2020
28
Review of Comorbidities of Hidradenitis Suppurativa: Implications for Daily Clinical Practice. 61
31955366 2020
29
Hidradenitis suppurativa and risk for development of Clostridium difficile colitis. 61
32010962 2020
30
Hidradenitis suppurativa and infections. 61
31885072 2020
31
An association between hidradenitis suppurativa and HIV. 61
31407315 2020
32
Psoriasis as a comorbidity of hidradenitis suppurativa. 61
31591714 2020
33
Effects of Zinc Supplementation on Inflammatory Skin Diseases: A Systematic Review of the Clinical Evidence. 61
31745908 2020
34
Apocrine glands are bystanders in hidradenitis suppurativa and their involvement is gender-specific. 61
32031713 2020
35
Associations of cutaneous and extracutaneous infections with hidradenitis suppurativa in U.S. children and adults. 61
31049925 2020
36
Pediatric Endoscopic Hidradenitis Treatment: A New Minimally Invasive Treatment for Pediatric Patients with Hidradenitis Suppurativa. 61
32017645 2020
37
Remission of severe hidradenitis suppurativa following chemotherapy for Hodgkin lymphoma. 61
31396947 2020
38
Analysis of Characteristics and Trends in Treatment Response of Hidradenitis Suppurativa Patients: A Southern US Cohort Study. 61
31935718 2020
39
A Phase II, Open Label Study of Bermekimab in Patients with Hidradenitis Suppurativa Shows Resolution of Inflammatory Lesions and Pain. 61
32004568 2020
40
Hidradenitis Suppurativa and Thyroid Disease: Systematic Review and Meta-Analysis. 61
31994934 2020
41
Complementary and Alternative Medicine Use in Patients With Hidradenitis Suppurativa. 61
31995122 2020
42
Identifying anaemia in a cohort of patients with hidradenitis suppurativa. 61
31374127 2020
43
Hidradenitis Suppurativa: The Disease Which Stimulates Researchers and Clinicians. 61
31955165 2020
44
Publication trends in hidradenitis suppurativa from 2008-2018. 61
31968146 2020
45
Mammillary Fistula as a Possible Manifestation of Hidradenitis Suppurativa. 61
31902443 2020
46
Review of imaging technologies used in Hidradenitis Suppurativa. 61
31595571 2020
47
Hidradenitis Suppurativa or Hidradenitis Suppurativa-Like Lesions Located on Amputation Stumps? Description of 2 Cases. 61
32021860 2020
48
Hidradenitis suppurativa has an enormous impact on patients' lives. 61
31302191 2020
49
Relationship between fecal calprotectin level and disease activity in patients with hidradenitis suppurativa. 61
31985885 2020
50
Infrared thermography and color Doppler: Two combined tools for assessing inflammation in hidradenitis suppurativa. 61
31342563 2020

Variations for Hidradenitis

Expression for Hidradenitis

Search GEO for disease gene expression data for Hidradenitis.

Pathways for Hidradenitis

Pathways related to Hidradenitis according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.87 TNF TLR4 PSEN1 NOD2 NCSTN LTA
2
Show member pathways
13.27 TNF PSENEN NCSTN KRT14 KRT10 DSG3
3
Show member pathways
12.27 TNF TLR4 NOD2 IL17A IL12RB1 IFNG
4 12.13 TNF TLR4 NOD2 CAMP
5
Show member pathways
12.09 KRT14 KRT10 DSG3 DSG1 DSC2 DSC1
6 11.97 TNF TLR4 NOD2 IFNG CAMP
7 11.81 TNF TLR4 LTA
8 11.8 TNF TLR4 IFNG
9
Show member pathways
11.76 TLR4 IL17A IL12RB1
10 11.74 KRT14 KRT10 DSG1 CAMP
11 11.7 TNF TLR4 IL17A IFNG
12 11.63 TNF IL17A IFNG
13
Show member pathways
11.59 PSENEN PSEN1 NCSTN
14 11.51 PSENEN PSEN1 NCSTN
15 11.49 TNF TLR4 LTA
16 11.44 TNF TLR4 IFNG
17
Show member pathways
11.43 TNF LTA IFNG
18 11.39 TNF TLR4 IFNG
19 11.36 PSENEN PSEN1 NCSTN
20 11.26 TNF LTA IL17A IL12RB1 IFNG
21
Show member pathways
11.21 TNF TLR4 LTA IL17A IL12RB1 IFNG
22 11.19 TNF IL17A IFNG
23 11.01 PSENEN PSEN1 NCSTN
24 10.77 PSENEN PSEN1 NCSTN
25 10.25 PSENEN PSEN1

GO Terms for Hidradenitis

Cellular components related to Hidradenitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.15 TNF TLR4 PSENEN PSEN1 NOD2 NCSTN
2 extracellular exosome GO:0070062 10.01 PIP NCSTN KRT14 KRT10 DSG3 DSC2
3 cell-cell junction GO:0005911 9.56 DSG3 DSG1 DSC2 DSC1
4 integral component of presynaptic membrane GO:0099056 9.5 PSENEN PSEN1 NCSTN
5 gamma-secretase complex GO:0070765 9.33 PSENEN PSEN1 NCSTN
6 desmosome GO:0030057 9.26 DSG3 DSG1 DSC2 DSC1
7 cornified envelope GO:0001533 9.02 KRT10 DSG3 DSG1 DSC2 DSC1

Biological processes related to Hidradenitis according to GeneCards Suite gene sharing:

(show top 50) (show all 52)
# Name GO ID Score Top Affiliating Genes
1 cell adhesion GO:0007155 10.11 PSEN1 DSG3 DSG1 DSC2 DSC1
2 immune response GO:0006955 10.07 TNF TLR4 LTA IL17A IFNG
3 neutrophil degranulation GO:0043312 10.07 PSEN1 NCSTN DSG1 DSC1 CAMP
4 positive regulation of gene expression GO:0010628 10.07 TNF TLR4 PSEN1 PIP IFNG
5 positive regulation of apoptotic process GO:0043065 10.02 TNF PSENEN PSEN1 NCSTN LTA
6 defense response to bacterium GO:0042742 9.99 TNF TLR4 NOD2 CAMP
7 positive regulation of protein phosphorylation GO:0001934 9.94 TNF PSEN1 IFNG CAMP
8 cellular response to lipopolysaccharide GO:0071222 9.94 TNF TLR4 NOD2 CAMP
9 homophilic cell adhesion via plasma membrane adhesion molecules GO:0007156 9.92 DSG3 DSG1 DSC2 DSC1
10 defense response to Gram-positive bacterium GO:0050830 9.89 TNF LTA CAMP
11 positive regulation of catalytic activity GO:0043085 9.87 PSENEN PSEN1 NCSTN
12 ephrin receptor signaling pathway GO:0048013 9.87 PSENEN PSEN1 NCSTN
13 positive regulation of JNK cascade GO:0046330 9.87 TNF TLR4 NOD2
14 regulation of inflammatory response GO:0050727 9.86 TNF TLR4 NOD2
15 cell-cell adhesion GO:0098609 9.85 PSEN1 DSG3 DSG1 DSC2 DSC1
16 positive regulation of MAP kinase activity GO:0043406 9.84 TNF PSEN1 NOD2
17 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.84 TNF TLR4 NOD2
18 positive regulation of interleukin-6 production GO:0032755 9.83 TNF TLR4 NOD2
19 protein processing GO:0016485 9.83 PSENEN PSEN1 NCSTN
20 humoral immune response GO:0006959 9.83 TNF LTA IFNG
21 positive regulation of nitric oxide biosynthetic process GO:0045429 9.79 TNF TLR4 IFNG
22 positive regulation of interleukin-6 secretion GO:2000778 9.77 TNF TLR4 IL17A
23 positive regulation of interleukin-8 production GO:0032757 9.77 TNF TLR4 NOD2
24 positive regulation of osteoclast differentiation GO:0045672 9.73 TNF IL17A IFNG
25 membrane protein ectodomain proteolysis GO:0006509 9.72 PSENEN PSEN1 NCSTN
26 amyloid-beta metabolic process GO:0050435 9.71 PSEN1 NCSTN
27 epithelial cell proliferation GO:0050673 9.71 PSEN1 NCSTN
28 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.71 TLR4 NOD2 IL17A
29 negative regulation of interleukin-17 production GO:0032700 9.7 TLR4 IFNG
30 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.7 TNF TLR4
31 positive regulation of tumor necrosis factor biosynthetic process GO:0042535 9.7 TLR4 PSEN1 IFNG
32 positive regulation of chemokine biosynthetic process GO:0045080 9.69 TNF IFNG
33 membrane protein intracellular domain proteolysis GO:0031293 9.69 PSENEN PSEN1 NCSTN
34 negative regulation of amyloid-beta clearance GO:1900222 9.68 TNF IFNG
35 positive regulation of MHC class II biosynthetic process GO:0045348 9.68 TLR4 IFNG
36 astrocyte activation GO:0048143 9.67 TNF PSEN1 IFNG
37 cellular response to peptidoglycan GO:0071224 9.65 NOD2 CAMP
38 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.65 TLR4 NOD2 IFNG
39 positive regulation of interleukin-23 production GO:0032747 9.63 IL17A IFNG
40 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.63 TNF LTA
41 positive regulation of interferon-gamma production GO:0032729 9.62 TNF TLR4 LTA IL12RB1
42 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.61 TNF IFNG
43 amyloid precursor protein metabolic process GO:0042982 9.61 PSENEN PSEN1 NCSTN
44 positive regulation of vitamin D biosynthetic process GO:0060557 9.58 TNF IFNG
45 positive regulation of nitrogen compound metabolic process GO:0051173 9.58 TNF IFNG
46 amyloid precursor protein catabolic process GO:0042987 9.58 PSENEN PSEN1 NCSTN
47 positive regulation of chronic inflammatory response to antigenic stimulus GO:0002876 9.57 TNF LTA
48 Notch receptor processing GO:0007220 9.54 PSENEN PSEN1 NCSTN
49 Notch receptor processing, ligand-dependent GO:0035333 9.43 PSENEN PSEN1 NCSTN
50 keratinization GO:0031424 9.43 KRT14 KRT10 DSG3 DSG1 DSC2 DSC1

Molecular functions related to Hidradenitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.92 TNF LTA IL17A IFNG

Sources for Hidradenitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....